ArticleNature immunology2021
Adenovirus vector vaccination reprograms pulmonary fibroblastic niches to support protective inflating memory CD8
Open access · bronzeAbstract read
In one paragraph
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Ex vivo model of functioning human lymph node reveals role for innate lymphocytes and stroma in response to vaccine adjuvant.Cell reports · 2025Article
- Early Notch signals from fibroblastic reticular cells program effector CD8+ T cell differentiation.The Journal of experimental medicine · 2025Article
- Transcriptomic responses of lung mesenchymal cells during pneumonia.JCI insight · 2025Article
- T and B cell responses in different immunization scenarios for COVID-19: a narrative review.Frontiers in immunology · 2025Review
- An off-target effect of class A CpG-oligonucleotides on suppressing the cyclic GMP-AMP synthase signaling in fibroblastic reticular cells.Frontiers in pharmacology · 2025Article
- Harnessing cellular immunity for next-generation vaccines against respiratory viruses: mechanisms, platforms, and optimization strategies.Frontiers in immunology · 2025Review
- Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants.Frontiers in immunology · 2025Article
- Antigen-presenting fibroblasts: emerging players in immune modulation and therapeutic targets.Theranostics · 2025Review
- Spatial visualization provides insight into immune modulation by an L-DBF vaccine formulation againstFrontiers in immunology · 2025Article
- Mucosal T-cell responses to chronic viral infections: Implications for vaccine design.Cellular & molecular immunology · 2024Review
- Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors.Journal for immunotherapy of cancer · 2024Article
- Innate immune responses against mRNA vaccine promote cellular immunity through IFN-β at the injection site.Nature communications · 2024Article
- Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration.Cell reports · 2024Article
- Novel and effective plasmid transfection protocols for functional analysis of genetic elements in human cardiac fibroblasts.PloS one · 2024Article
- Trained immunity of alveolar macrophages enhances injury resolution via KLF4-MERTK-mediated efferocytosis.The Journal of experimental medicine · 2023Article
- Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside.The Journal of clinical investigation · 2023Review
- PI16Nature immunology · 2023Article
- Granzyme B + CD8 + T cells with terminal differentiated effector signature determine multiple sclerosis progression.Journal of neuroinflammation · 2023Article
- The advent of immune stimulating CAFs in cancer.Nature reviews. Cancer · 2023Review
- Editorial: Adaptive immunity to respiratory pathogens.Frontiers in immunology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 3 countries.
Jovana CupovicInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Sandra S RingInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Lucas OnderInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Julia M ColstonPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-3337-2455
Mechthild LütgeInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.ORCID http://orcid.org/0000-0001-9011-5319
Hung-Wei ChengInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Angelina De MartinInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Nicholas M ProvinePeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-9694-2216
Lukas FlatzInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Annette OxeniusInstitute of Microbiology, ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-2079-2354
Elke ScandellaInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Philippe KrebsInstitute of Pathology, University of Berne, Berne, Switzerland.ORCID http://orcid.org/0000-0003-4918-6654
Daniel EngelerDepartment of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland.ORCID http://orcid.org/0000-0003-1383-4701
Paul Klenerman *Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. paul.klenerman@medawar.ox.ac.uk.ORCID http://orcid.org/0000-0003-4307-9161
Burkhard Ludewig *Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. burkhard.ludewig@kssg.ch.ORCID http://orcid.org/0000-0002-7685-573X
Kantonsspital St. Gallen · CHUniversity of Oxford · GBETH Zurich · CHUniversity of Bern · CHUniversity of Zurich · CH
Funding
Cancer Research UK 23521Cancer Research UK 29991Medical Research Council MR/R014485/1Swiss National Science Foundation 159188Swiss National Science Foundation 166500Wellcome Trust 099897Wellcome Trust 109965Wellcome Trust 109965/Z/15/Z
Abstract
Pathogens and vaccines that produce persisting antigens can generate expanded pools of effector memory CD8
Indexed as
AdenoviridaeAnimalsCD8-Positive T-LymphocytesCell Line, TumorChemokine CCL19ChimeraEpitopes, T-LymphocyteFibroblastsGenetic VectorsHumansImmunologic MemoryInterleukin-33LungLymphocyte ActivationMelanoma, ExperimentalMiceCcl19 protein, mouseChemokine CCL19Epitopes, T-LymphocyteIl33 protein, mouseInterleukin-33
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.